It isn't known whether Bausch + Lomb and/or Goldman is in contact with either Blackstone or TPG. According to the FT, several private equity funds mulling offers have dropped out of the race.

including Bausch + Lomb contact lens brands such as Bausch + Lomb INFUSE ®, Bausch + Lomb ULTRA ® and Biotrue ® ONEday. Over-the-counter products will include LUMIFY ® redness reliever eye ...

H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Bausch + Lomb Corporation (BLCO – Research Report) today and set a price target of $23.00. Yi Chen has given his Buy rating due to a ...

Bausch + Lomb's received approval from the Food and Drug Administration for enVista Envy's full range of vision intraocular lens. The Canadian eye-health company said enVista offers a continuous ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Bausch + Lomb scaled up its revenue guidance for the year after swinging to a profit in the latest quarter on the back of sales growth in each of its business segments. The Canadian eye-health ...

The stock of eyecare company Bausch + Lomb Corp. was up 14%on Monday, after the Financial Times reported that the company is considering selling itself as a way to extricate itself from its ...

Bausch + Lomb shares surged Monday following reports Blackstone and TPG are considering teaming up to buy the eyecare company. A bid from Blackstone and TPG could reportedly value the company ...

Bausch & Lomb (NYSE:BLCO) jumped 7.5% on a report that private equity firms TPG (TPG) and Blackstone (BX) are working on a joint bid for the eyecare company. Several other PE shops that have been ...

Continued progress on the buyout of Bausch & Lomb is lifting shares, with the stock up over 6% at the time of writing. Financial Times reported on Oct. 14 that two prominent figures involved in ...

Monday was an eventful day for Bausch + Lomb (NYSE: BLCO). The eye care specialist's major piece of internal news was that it earned its latest Food and Drug Administration (FDA) approval.